Xeris Pharmaceuticals

Update in progress

XERS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Based in Chicago, Illinois, it markets Gvoke, a ready-to-use glucagon for severe hypoglycemia in children and adults; Keveyis for periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia in adults with Cushing’s syndrome. It is developing XP-8121, a weekly subcutaneous levothyroxine for hypothyroidism in Phase 3 trials. Incorporated 2005.

Company score

Sentiment: 0.33; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.45; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.16; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive